At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMRX Immuneering Corp
Trading 06-15 11:28:46 EDT
4.28
+0.09
+2.15%
High4.33Low4.23Vol337.89K
Open4.28D1 Closing4.19Amplitude2.39%
Mkt Cap276.36MTradable Cap232.88MTotal Shares64.57M
T/O1.44MT/O Rate0.62%Tradable Shares54.41M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Immuneering Names Andrew Gengos as CFO
MT Newswires Live  ·  20:58
Immuneering Names Andrew Gengos as CFO
Immuneering Names Andrew Gengos Chief Financial Officer
Dow Jones  ·  19:53
Immuneering Names Andrew Gengos Chief Financial Officer
Immuneering - Appoints Andrew Gengos as Chief Financial Officer Effective July 16, 2026
THOMSON REUTERS  ·  19:30
Immuneering - Appoints Andrew Gengos as Chief Financial Officer Effective July 16, 2026
Press Release: Immuneering Appoints Andrew Gengos as Chief Financial Officer
Dow Jones  ·  19:30
Press Release: Immuneering Appoints Andrew Gengos as Chief Financial Officer
Immuneering Shareholders Approve Directors and Auditor at Meeting
TIPRANKS  ·  06-12
Immuneering Shareholders Approve Directors and Auditor at Meeting
Immuneering's Phase 3 Trial of Atebimetinib Plus mGnP to Treat Pancreatic Cancer Doses First Patient
MT Newswires Live  ·  06-11
Immuneering's Phase 3 Trial of Atebimetinib Plus mGnP to Treat Pancreatic Cancer Doses First Patient
Immuneering doses first patient in Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer
Reuters  ·  06-11
Immuneering doses first patient in Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer
Immuneering - Topline Data From Phase 3 Trial Expected in Mid-2028
THOMSON REUTERS  ·  06-11
Immuneering - Topline Data From Phase 3 Trial Expected in Mid-2028
Immuneering Buy Rating Reaffirmed as Analyst Sees ASCO Sell-Off as Overdone; $11 Price Target Maintained
TIPRANKS  ·  06-02
Immuneering Buy Rating Reaffirmed as Analyst Sees ASCO Sell-Off as Overdone; $11 Price Target Maintained
Immuneering Advances Atebimetinib With Positive Phase 2a Results
TIPRANKS  ·  06-02
Immuneering Advances Atebimetinib With Positive Phase 2a Results
Immuneering - 17.3 Month Median Overall Survival Observed in 320 Mg ITT Population as of April 24, 2026 - SEC Filing
THOMSON REUTERS  ·  06-02
Immuneering - 17.3 Month Median Overall Survival Observed in 320 Mg ITT Population as of April 24, 2026 - SEC Filing
Immuneering - Announces Updated Phase 2a Data for Atebimetinib in Pancreatic Cancer - SEC Filing
THOMSON REUTERS  ·  06-02
Immuneering - Announces Updated Phase 2a Data for Atebimetinib in Pancreatic Cancer - SEC Filing
Immuneering says atebimetinib plus chemo posts 17.3-month median survival in Phase 2a first-line pancreatic cancer study
Reuters  ·  06-01
Immuneering says atebimetinib plus chemo posts 17.3-month median survival in Phase 2a first-line pancreatic cancer study
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
GlobeNewswire  ·  06-01
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Cencora (COR)
TIPRANKS  ·  05-22
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Cencora (COR)
Immuneering says atebimetinib-chemo trial shows 17.3-month median survival in pancreatic cancer
Reuters  ·  05-22
Immuneering says atebimetinib-chemo trial shows 17.3-month median survival in pancreatic cancer
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated With Atebimetinib Plus Chemotherapy
THOMSON REUTERS  ·  05-22
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated With Atebimetinib Plus Chemotherapy
Immuneering Corp - Only Anemia (16%) and Neutropenia (18%) Grade 3+ Adverse Events in ≥10% of Patients
THOMSON REUTERS  ·  05-22
Immuneering Corp - Only Anemia (16%) and Neutropenia (18%) Grade 3+ Adverse Events in ≥10% of Patients
Immuneering Corp - Full Data From 55 Patients to Be Presented at Asco on June 1, 2026
THOMSON REUTERS  ·  05-22
Immuneering Corp - Full Data From 55 Patients to Be Presented at Asco on June 1, 2026
Immuneering Corp - Reports 17.3-Month Median Overall Survival as of April 24, 2026 Data Cutoff
THOMSON REUTERS  ·  05-22
Immuneering Corp - Reports 17.3-Month Median Overall Survival as of April 24, 2026 Data Cutoff

Introduction

Company Name.
Immuneering Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Issue price:
--